Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy

Descrizione del progetto

Diagnosi precoce e interventi personalizzati per le malattie epatiche

La cirrosi epatica e il cancro al fegato sono molto diffusi in Europa e causano 300 000 decessi all’anno. Fattori eziologici come l’obesità, il diabete e il consumo di alcol sono in aumento e contribuiscono al crescente carico di malattie epatiche. Purtroppo, la fibrosi epatica spesso non viene individuata fino agli stadi avanzati, limitando le opzioni terapeutiche al trapianto. In questo contesto, il progetto LIVERAIM, finanziato dall’UE, mira a sperimentare una piattaforma di screening che utilizzi biomarcatori per la diagnosi precoce e interventi terapeutici personalizzati. In particolare, il progetto riunisce centri clinici e partner industriali per sviluppare una piattaforma di screening. Analizzando i campioni della biobanca provenienti da 25 000 soggetti e conducendo uno studio controllato randomizzato che coinvolge 100 000 individui in sei paesi dell’UE, LIVERAIM mira a convalidare interventi terapeutici personalizzati.

Obiettivo

Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, causing 300K deaths per year in Europe. Predominant etiological factors are obesity, type2 diabetes, and increased alcohol in-take, which are all on the rise. It is predicted that healthy life expectancy will decrease in Europe over the next 30 years because of deaths due to liver disease. Liver cirrhosis develops after a very long period of asymptomatic liver fibrosis, staying undetected until patients develop severe complications due to cirrhosis or liver cancer. Currently the only effective treatment available is liver transplantation which is not applicable to all patients. If fibrosis is detected early, to target the course of liver disease, then liver fibrosis is reversible. The LIVERAIM project concentrates a team of renowned clinical centres and Industrial partners, including SMEs, with great expertise in the field of Liver Disease, the aim being to design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions. A large number of existing biomarkers will be tested for fibrosis prediction accuracy using biobank plasma samples from 40,000 subjects from previous H2020 EU-funded cohorts. LIVERAIM will develop a screening platform with biomarkers using AI for personalized early diagnosis of fibrosis to be validated in a RCT of 100K subjects from 6 representative EU countries. The platform will be linked to tailored, personalized therapeutic interventions to halt fibrosis progression. With LIVERAIM, early diagnosis and personalized intervention can stop liver disease progression, help decrease morbidity and mortality and the associated societal burdens both economic and health inequity.

Coordinatore

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Contribution nette de l'UE
€ 2 874 898,03
Indirizzo
CARRER ROSSELLO 149
08036 Barcelona
Spagna

Mostra sulla mappa

Regione
Este Cataluña Barcelona
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 4 668 481,26

Partecipanti (26)

Partner (4)